Market Spotlight: Osteoarthritis and Osteoarthritis Pain
Market Spotlight: Osteoarthritis and Osteoarthritis Pain
$1,318.00
This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were 552.0 million prevalent cases of osteoarthritis (knee or hip) in adults aged 45 years and older worldwide, and forecasts that number to increase to 657.7 million prevalent cases by 2030.
- The global prevalence of osteoarthritis in adults aged 45 years and older is estimated to be 22.9%. The approved drugs in the osteoarthritis and osteoarthritis pain space focus on a wide variety of targets. The majority of these therapies are administered via the oral route, with the remainder being topical, intraarticular, and transdermal formulations.
- Half of all the industry-sponsored drugs in active clinical development for osteoarthritis and osteoarthritis pain are in Phase II. Therapies in development for osteoarthritis and osteoarthritis pain focus on a wide variety of targets. The largest proportion of pipeline drugs are administered via the intraarticular route.
- High-impact upcoming events for drugs in the osteoarthritis and osteoarthritis pain space comprise topline Phase II trial results for MEDI7352, SL-1002, and EP-104IAR; topline Phase IIb trial results for MM-II and XT-150; and topline Phase III trial results for TLC599, lorecivivint, and Zilosul.
- The overall likelihood of approval of a Phase I osteoarthritis asset is 3.6%, and the average probability a drug advances from Phase III is 40%. Drugs, on average, take 17.4 years from Phase I to approval, compared to 17.3 years in the overall rheumatology (non autoimmune) space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for osteoarthritis have been in the early and mid-phases of development, with 57% of trials in Phase I–II, and 43% in Phase III–IV.
- The US has a substantial lead in the number of osteoarthritis clinical trials globally. The UK and Germany lead the major European markets, while South Korea has the top spot in Asia.
- Clinical trial activity in the osteoarthritis space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for osteoarthritis, with 97 trials.
- Pfizer leads industry sponsors with the highest overall number of clinical trials for osteoarthritis.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Non-pharmacological treatment
9 Pharmacological treatment
10 Surgery
11 EPIDEMIOLOGY
14 MARKETED DRUGS
19 PIPELINE DRUGS
28 RECENT EVENTS AND ANALYST OPINION
28 CNTX-4975 for Osteoarthritis Pain (April 29, 2022)
29 Ampion for Osteoarthritis Pain (April 20, 2022)
30 Ampion for Osteoarthritis Pain (September 15, 2021)
30 AmnioFix for Osteoarthritis (September 13, 2021)
33 KEY UPCOMING EVENTS
34 KEY REGULATORY EVENTS
34 Pfizer/Lilly Discontinue Tanezumab, The Likely End For A Class Dogged By Safety
35 PROBABILITY OF SUCCESS
36 LICENSING AND ASSET ACQUISITION DEALS
36 Hansoh Gets Commercial Rights To KiOmed’s Knee Osteoarthritis Therapy
36 Shionogi Gets Japanese Rights To Grünenthal Pain Injectable
36 Endo Picks Up US Rights To TLC’s Late-Stage Pain Therapy
36 Medipost To Become Biggest Shareholder Of OmniaBio
37 Juniper Acquires Kolon’s Cell-Mediated Gene Therapy For Knee Osteoarthritis
37 CDRI Licenses Caviunin-Based Drug Compositions to Aveta Biomics
37 Pacira Aims For Non-Opioid Pipeline Growth With Flexion Buy
39 REVENUE OPPORTUNITY
41 CLINICAL TRIAL LANDSCAPE
42 Sponsors by status
43 Sponsors by phase
44 Recent events
45 BIBLIOGRAPHY
46 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of osteoarthritis (knee or hip), 2021–30
19 Figure 2: Overview of pipeline drugs for osteoarthritis and osteoarthritis pain in the US
19 Figure 3: Pipeline drugs for osteoarthritis and osteoarthritis pain, by company
20 Figure 4: Pipeline drugs for osteoarthritis and osteoarthritis pain, by drug type
20 Figure 5: Pipeline drugs for osteoarthritis and osteoarthritis pain, by classification
32 Figure 6: AmnioFix for Osteoarthritis (September 13, 2021): Phase IIb – dHACM (Knee Osteoarthritis)
33 Figure 7: Key upcoming events in osteoarthritis and osteoarthritis pain
35 Figure 8: Probability of success in the osteoarthritis pipeline
41 Figure 9: Clinical trials in osteoarthritis
41 Figure 10: Top 10 drugs for clinical trials in osteoarthritis
42 Figure 11: Top 10 companies for clinical trials in osteoarthritis
42 Figure 12: Trial locations in osteoarthritis
43 Figure 13: Osteoarthritis trials status
44 Figure 14: Osteoarthritis trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of osteoarthritis (knee or hip), 2021–30
15 Table 2: Marketed drugs for osteoarthritis and osteoarthritis pain
21 Table 3: Pipeline drugs for osteoarthritis and osteoarthritis pain in the US
28 Table 4: CNTX-4975 for Osteoarthritis Pain (April 29, 2022)
29 Table 5: Ampion for Osteoarthritis Pain (April 20, 2022)
30 Table 6: Ampion for Osteoarthritis Pain (September 15, 2021)
31 Table 7: AmnioFix for Osteoarthritis (September 13, 2021)
39 Table 8: Historical global sales, by drug ($m), 2017–21
40 Table 9: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL) 
Sign up to the